Sandramycin, a novel antitumor antibiotic produced by a Nocardioides sp. Production, isolation, characterization and biological properties.
A new antitumor antibiotic, sandramycin, was isolated from cultured broth of a Nocardioides sp. (ATCC 39419) and purified by solvent partition and column chromatography. Sandramycin, a new depsipeptide, was moderately active in vitro against Gram-positive organisms and in vivo against leukemia P388 in mice.
Matson
J A
JA
Pharmaceutical Research and Development Division, Bristol-Myers Company, Wallingford, Connecticut 06492.
Bush
J A
JA
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000302:isolation & purification* / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D006094:Gram-Positive Bacteria / Q000187:drug effects; D007941:Leukemia P388 / Q000188:drug therapy; D051379:Mice; D008826:Microbial Sensitivity Tests; D009618:Nocardiaceae / Q000032:analysis; D010456:Peptides, Cyclic / Q000302:isolation & purification / Q000627:therapeutic use; D011804:Quinolines / Q000302:isolation & purification* / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D010456:Peptides, Cyclic; D011804:Quinolines; C063090:sandramycin